1-10 of 10
Soheil Meshinchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group

Available to Purchase
Vivek M. Shastri, Lata Chauhan, Mohammed Gbadamosi, Todd A. Alonzo, Yi-Cheng Wang, Richard Aplenc, Betsy A. Hirsch, Edward A. Kolb, Alan S. Gamis, Soheil Meshinchi, Jatinder K. Lamba
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (5): 890–898.
https://doi.org/10.1158/1078-0432.CCR-23-2073
Published: 03 March 2025
View articletitled, DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group
Open the PDF for DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group in another window
Includes: Supplementary data
Journal Articles

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia

Open Access
Quy Le, Sommer Castro, Thao Tang, Anisha M. Loeb, Tiffany Hylkema, Cyd Nourigat McKay, LaKeisha Perkins, Shivani Srivastava, Lindsey Call, Jenny Smith, Amanda Leonti, Rhonda Ries, Laura Pardo, Michael R. Loken, Colin Correnti, Salvatore Fiorenza, Cameron J. Turtle, Stanley Riddell, Katherine Tarlock, Soheil Meshinchi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5718–5730.
https://doi.org/10.1158/1078-0432.CCR-21-1546
Published: 15 October 2021
View articletitled, Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Open the PDF for Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

Available to Purchase
Jenny L. Smith, Rhonda E. Ries, Tiffany Hylkema, Todd A. Alonzo, Robert B. Gerbing, Marianne T. Santaguida, Lisa Eidenschink Brodersen, Laura Pardo, Carrie L. Cummings, Keith R. Loeb, Quy Le, Suzan Imren, Amanda R. Leonti, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Jason E. Farrar, Timothy J. Triche, Jr, Cu Nguyen, Daoud Meerzaman, Michael R. Loken, Vivian G. Oehler, Hamid Bolouri, Soheil Meshinchi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 726–737.
https://doi.org/10.1158/1078-0432.CCR-19-1800
Published: 03 February 2020
View articletitled, Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study
Open the PDF for Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study in another window
Includes: Supplementary data
Journal Articles

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

Available to Purchase
Katherine Tarlock, Todd A. Alonzo, Yi-Cheng Wang, Robert B. Gerbing, Rhonda Ries, Michael R. Loken, Laura Pardo, Tiffany Hylkema, Jason Joaquin, Leela Sarukkai, Susana C. Raimondi, Betsy Hirsch, Lillian Sung, Richard Aplenc, Irwin Bernstein, Alan S. Gamis, Soheil Meshinchi, Jessica A. Pollard
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 5038–5048.
https://doi.org/10.1158/1078-0432.CCR-18-1897
Published: 15 August 2019
View articletitled, Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Open the PDF for Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Available to Purchase
Katherine Tarlock, Todd A. Alonzo, Michael R. Loken, Robert B. Gerbing, Rhonda E. Ries, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Samir B. Kahwash, Amy McKenney, E. Anders Kolb, Alan S. Gamis, Soheil Meshinchi
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3649–3656.
https://doi.org/10.1158/1078-0432.CCR-16-2353
Published: 13 July 2017
View articletitled, Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Open the PDF for Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group in another window
Includes: Supplementary data
Journal Articles

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Available to Purchase
Katherine Tarlock, Todd A. Alonzo, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Lillian Sung, Jessica A. Pollard, Richard Aplenc, Michael R. Loken, Alan S. Gamis, Soheil Meshinchi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 1951–1957.
https://doi.org/10.1158/1078-0432.CCR-15-1349
Published: 14 April 2016
View articletitled, Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Open the PDF for Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group in another window
Includes: Supplementary data
Journal Articles

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Available to Purchase
George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3187–3195.
https://doi.org/10.1158/1078-0432.CCR-14-2684
Published: 14 July 2015
View articletitled, Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Open the PDF for Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group in another window
Includes: Supplementary data
Journal Articles

Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy

Available to Purchase
Leslie Mortland, Todd A. Alonzo, Roland B. Walter, Robert B. Gerbing, Amit K. Mitra, Jessica A. Pollard, Michael R. Loken, Betsy Hirsch, Susana Raimondi, Janet Franklin, Stanley Pounds, Xueyuan Cao, Jeffrey E. Rubnitz, Raul C. Ribeiro, Alan Gamis, Soheil Meshinchi, Jatinder K. Lamba
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1620–1627.
https://doi.org/10.1158/1078-0432.CCR-12-3115
Published: 14 March 2013
View articletitled, Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy
Open the PDF for Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031

Available to Purchase
Soheil Meshinchi, Stephen P. Hunger, Richard Aplenc, Peter C. Adamson, J. Milburn Jessup
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1547–1554.
https://doi.org/10.1158/1078-0432.CCR-11-2205
Published: 14 March 2012
View articletitled, Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031
Open the PDF for Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031 in another window
Journal Articles

Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia

Available to Purchase
Soheil Meshinchi, Frederick R. Appelbaum
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4263–4269.
https://doi.org/10.1158/1078-0432.CCR-08-1123
Published: 01 July 2009
View articletitled, Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Open the PDF for Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia in another window